VEGFA and neoplasm: The anti-angiogenic therapies hinder the immunosuppressive effect created by VEGF or its receptors by enhanced infiltration of mature dendritic cells and effector T cells into the tumor cells and reduced infiltration of regulatory T cells and myeloid derived suppressor cells.